Desjardins Issues Negative Outlook for TSE:INO Earnings

Inovalis Real Estate Investment Trust (TSE:INO) – Research analysts at Desjardins dropped their Q4 2024 earnings per share estimates for shares of Inovalis Real Estate Investment Trust in a research report issued on Monday, November 11th. Desjardins analyst A. Leon now anticipates that the company will post earnings per share of ($0.01) for the quarter, down from their prior estimate of $0.01. Desjardins also issued estimates for Inovalis Real Estate Investment Trust’s FY2025 earnings at ($0.06) EPS and FY2026 earnings at ($0.14) EPS.

Inovalis Real Estate Investment Trust Price Performance

Inovalis Real Estate Investment Trust (TSE:INO) last released its quarterly earnings data on Thursday, November 7th. The company reported C($0.29) EPS for the quarter. The business had revenue of C$3.52 million for the quarter.

Inovalis Real Estate Investment Trust Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.